Jazz Pharmaceuticals(US:JAZZ)2024-07-31 23:41Financial Performance & Guidance - Total revenues for 2024 are expected to be between $4 billion and $4.1 billion[8], representing a +6% increase at the guidance midpoint[8, 35] - Adjusted net income (ANI) for 2024 is projected to be between $1.275 billion and $1.350 billion[8], and adjusted EPS is expected to be $19.20 - $20.30[8] - The company anticipates double-digit percentage growth of Xywav, Epidiolex, and Rylaze combined in 2024[8, 13] - Expect high-sodium AG royalty revenue to exceed $200 million in 2024[14] Product Performance - Epidiolex revenues grew 22% year-over-year (YoY)[8, 18] - Xywav revenues grew 13% YoY[8, 14] - Oncology revenues grew 10% YoY[8] - Rylaze revenues grew 6% YoY[8, 21] - Zepzelca revenues grew 15% YoY[8, 24] Pipeline Development - Zanidatamab BLA granted Priority Review by U S FDA with a PDUFA date of November 29, 2024[8, 28] - Phase 3 top-line PFS data in GEA for Zanidatamab is estimated for 2Q25[8] - Phase 3 top-line data readout for Epidyolex in Japan is expected in 2H24[8, 27] - Phase 3 top-line PFS Readout for Zepzelca in 1L ES SCLC combo with Tecentriq is expected by the end of 2024[8, 27]